EpiCept Corporation
EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene(TM) and EpiCept(TM) NP-1 Cream
Published in Medical Letter on the CDC and FDA, February 10th, 2008
EpiCept announced that its Marketing Authorization Application (MAA) seeking marketing approval for Ceplene in the European Union has advanced to the next important step. The Company has submitted full written responses to the Day 180 List of Outstanding Issues to the Committee for Human Medicinal Products (CHMP). With this response, EpiCept believes it has now addressed all outstanding issues related to the MAA.
The next regulatory milestone for Ceplene will be...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Depression
Selective reporting of antidepressant trials exaggerates drug effectiveness - Pediatrics
National study will look at German-made heart pump for children needing heart transplants - Atrial Fibrillation
Independent Clinical Trial Finds HIFU Surgical Ablation Effective in Treating Atrial Fibrillation - Clinical Research
Scientists at Amgen, Inc. discuss research in clinical research - Diabetes
Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Body's Own Naturally Occurring Stem Cells - Regulatory Actions
Stryker Issues Statement Regarding FDA Warning Letter - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
